biostudies-literatureWhisenant JGNCI NIH HHSInternational Association for the Study of Lung Cancer661-674https://www.ebi.ac.uk/biostudies/studies/S-EPMC8804493biostudies-literatureUnknown17(5)<h4>Introduction</h4>Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far.<h4>Methods</h4>Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics.<h4>Results</h4>As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis. With a mean obsJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerA Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.PMC8804493UG1 CA233290P30 CA008748Porcu LGeraedts EMazzoni FBrahmer JHirsch FRGarassino MCFelip ECoate LPasello GPeters SHellmann MDAzab MABar JTorri VAzzam AYTERAVOLT study groupMonnet IBestvina CMGenova CMarmarelis MUnk MHorn LTrama ABarlesi FBaena JIbrahim ECeresoli GLFidler MJZhumagaliyeva ANAujayeb AMascaux CGarrido PWakelee HMazieres JBria EHuang LCMorgillo FWong SKRizvi HAgustoni FGomes FTapan UScotti VRogado JCortellini AMountzios GBaggi ADingemans AMRoca EGomez-Martin CNadal EGrosso FBatra UPopat SSerrano-Montero GMetivier ACPuri SArrieta OWhisenant JGKhan HHalmos BBoudjemaa ABlaquier JBReinmuth NBettini ACPresley CJReckamp KLAvrillon VLo Russo GLeighl NBPatel JDFalchero LfalseA Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry.<h4>Introduction</h4>Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far.<h4>Methods</h4>Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics.<h4>Results</h4>As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis. With a mean obs2022-01-01T00:00:00Z2022 May2025-04-03T21:30:07.68Z2025-04-03T21:30:07.68ZS-EPMC88044933512108610.1016/j.jtho.2021.12.015